Metabolic & Endocrine
Type 2 Diabetic Patients
0
Pipeline Programs↗
2
Active Trials↗
19
Companies Involved↗
Type 2 Diabetic Patients is an early-stage landscape with 0 programs across 19 companies. The most active players are Sanofi, Boehringer Ingelheim, Astellas.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
124
clinical trials
Completed96 · 77%
Unknown status15 · 12%
Terminated10 · 8%
Active, not recruiting1 · 1%
Recruiting1 · 1%
Withdrawn1 · 1%
Clinical Trials
Trial Activity
124 trials
JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients
Completed·—·Phase 4·NCT01269996·71 enrolled
Fenofibrate Versus Curcumin in Type 2 Diabetic Patients
Completed·—·Phase 4·NCT04528212·60 enrolled
Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients
Completed·—·Phase 4·NCT00742976·24 enrolled
Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)
Completed·—·Phase 3·NCT00551876·214 enrolled
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)